The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis
Clinical Scorecard: Evaluating the Effectiveness of Combining Angiogenesis Inhibitors with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with advanced breast cancer, particularly those with triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+) disease, including those progressing from early-stage disease.
Care Setting
Key Highlights
PFS benefit varied by subtype: mAbs outperformed TKIs in TNBC (HR 0.59), while TKIs trended better in HR+ disease (HR 0.67).
Guideline-Based Recommendations
Diagnosis
Management
Consider combination of angiogenesis inhibitors with chemotherapy for improved PFS in advanced breast cancer.
Assess patient eligibility for combination therapy based on specific biomarkers.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Combination therapy may enhance response rates but requires careful management of associated toxicities, including specific monitoring protocols.
Clinical Best Practices
Utilize mAbs for TNBC and TKIs for HR+ disease to optimize treatment outcomes.
Implement proactive management strategies for treatment-related toxicities, including specific monitoring protocols.
